Hypercoagulable States

In this application-based continuing pharmacy education activity Dr Anuja Rizal, PharmD, RPh, CACP discusses various genetic conditions and the resulting modifications to anticoagulation therapy.

Target Audience

Pharmacists who are interested in the management of patients on anticoagulation therapy.
This activity is not accredited for technicians.

Learning Objectives

At the conclusion of the activity, pharmacists will be able to:

  • Describe inherited hypercoagulable states
  • Describe acquired hypercoagulable states
  • Discuss management strategies for various hypercoagulable states including Antithrombin III Deficiency, Protein C or S Deficiency, Factor V Leiden, Prothrombin gene mutation, Hyperhomocysteinemia and Antiphospholipid Antibody Syndrome

Activity Faculty

Anuja Rizal, Pharm.D., R.Ph., CACP
Anticoagulation Clinic Coordinator, The University of Connecticut Health Center, Farmington, CT

Faculty Disclosure

In accordance with the Accreditation Council for Pharmacy Education (ACPE) Criteria for Quality and Interpretive Guidelines, The University of Connecticut School of Pharmacy requires that faculty disclose any relationship that the faculty may have with commercial entities whose products or services may be mentioned in the activity.

Dr Anuja Rizal, PharmD, RPh, CACP has nothing to disclose.

Program Fees

Click on the registration link to register for this activity.  The cost is $15 if registering separately or all 13 activities for $120.00 if bundling.  See registration site for details.

Grant Funding

This activity has been supported by an educational grant from CSL Behring

 

ACPE logoThe University of Connecticut, School of Pharmacy, is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.  1.0 contact hour (0.10 CEU) will be awarded to pharmacists who view the presentation, pass the learning assessment with a grade of 70% or better and complete an evaluation. (ACPE #0009-0000-15-082-H01-P)  CE credits will be electronically uploaded to the CPE Monitor System within 72 hours after successfully completing the online quiz and evaluation.

Initial release date:  May 15, 2016
Planned expiration date:  May 15, 2019

Disclaimer:
The material presented here does not necessarily reflect the views of The University of Connecticut School of Pharmacy or its co-sponsor affiliates. These materials may discuss uses and dosages for therapeutic products, processes, procedures and inferred diagnoses that have not been approved by the United States Food and Drug Administration. A qualified health care professional should be consulted before using any therapeutic product discussed. All readers and continuing education participants should verify all information and data before treating patients or employing any therapies described in this continuing education activity.